
Karyopharm to Seek Accelerated Approval for Selinexor in Myelofibrosis
After productive regulatory discussions, Karyopharm Therapeutics plans to file for U.S. approval of its selinexor-ruxolitinib combination by August 2026. The company intends to leverage the accelerated approval pathway, citing compelling spleen volume reduction data observed during the Phase 3 SENTRY clinical trial as a surrogate endpoint for patient survival.

























